TY - JOUR
T1 - Eight Years of Growth Hormone Treatment in Children With Prader-Willi Syndrome: Maintaining the Positive Effects
AU - Bakker, N. E.
AU - Kuppens, R. J.
AU - Siemensma, E. P. C.
AU - Tummers-de Lind van Wijngaarden, R. F. A.
AU - Festen, D. A. M.
AU - Bindels-de Heus, G. C. B.
AU - Bocca, G.
AU - Haring, D. A. J. P.
AU - Hoorweg-Nijman, J. J. G.
AU - Houdijk, E. C. A. M.
AU - Jira, P. E.
AU - Lunshof, L.
AU - Odink, R. J.
AU - Oostdijk, W.
AU - Rotteveel, J.
AU - Schroor, E. J.
AU - van Alfen, A. A. E. M.
AU - van Leeuwen, M.
AU - van Pinxteren-Nagler, E.
AU - van Wieringen, H.
AU - Vreuls, R. C. F. M.
AU - Zwaveling-Soonawala, N.
AU - de Ridder, M. A. J.
AU - Hokken-Koelega, A. C. S.
PY - 2013
Y1 - 2013
N2 - Background: The most important reason for treating children with Prader-Willi syndrome (PWS) with GH is to optimize their body composition. Objectives: The aim of this ongoing study was to determine whether long-term GH treatment can counteract the clinical course of increasing obesity in PWS by maintaining the improved body composition brought during early treatment. Setting: This was a multicenter prospective cohort study. Methods: We have been following 60 prepubertal children for 8 years of continuous GH treatment (1 mg/m(2)/d congruent to 0.035 mg/kg/d) and used the same dual-energy x-ray absorptiometry machine for annual measurements of lean body mass and percent fat. Results: After a significant increase during the first year of GH treatment (P <.0001), lean body mass remained stable for 7 years at a level above baseline (P <.0001). After a significant decrease in the first year, percent fat SD score (SDS) and body mass index SDS remained stable at a level not significantly higher than at baseline (P = .06, P = .14, resp.). However, body mass index SDSPWS was significantly lower after 8 years of GH treatment than at baseline (P <.0001). After 8 years of treatment, height SDS and head circumference SDS had completely normalized. IGF-1 SDS increased to +2.36 SDS during the first year of treatment (P <.0001) and remained stable since then. GH treatment did not adversely affect glucose homeostasis, serum lipids, blood pressure, and bone maturation. Conclusion: This 8-year study demonstrates that GH treatment is a potent force for counteracting the clinical course of obesity in children with PWS
AB - Background: The most important reason for treating children with Prader-Willi syndrome (PWS) with GH is to optimize their body composition. Objectives: The aim of this ongoing study was to determine whether long-term GH treatment can counteract the clinical course of increasing obesity in PWS by maintaining the improved body composition brought during early treatment. Setting: This was a multicenter prospective cohort study. Methods: We have been following 60 prepubertal children for 8 years of continuous GH treatment (1 mg/m(2)/d congruent to 0.035 mg/kg/d) and used the same dual-energy x-ray absorptiometry machine for annual measurements of lean body mass and percent fat. Results: After a significant increase during the first year of GH treatment (P <.0001), lean body mass remained stable for 7 years at a level above baseline (P <.0001). After a significant decrease in the first year, percent fat SD score (SDS) and body mass index SDS remained stable at a level not significantly higher than at baseline (P = .06, P = .14, resp.). However, body mass index SDSPWS was significantly lower after 8 years of GH treatment than at baseline (P <.0001). After 8 years of treatment, height SDS and head circumference SDS had completely normalized. IGF-1 SDS increased to +2.36 SDS during the first year of treatment (P <.0001) and remained stable since then. GH treatment did not adversely affect glucose homeostasis, serum lipids, blood pressure, and bone maturation. Conclusion: This 8-year study demonstrates that GH treatment is a potent force for counteracting the clinical course of obesity in children with PWS
U2 - https://doi.org/10.1210/jc.2013-2012
DO - https://doi.org/10.1210/jc.2013-2012
M3 - Article
C2 - 24001750
SN - 0021-972X
VL - 98
SP - 4013
EP - 4022
JO - Journal of clinical endocrinology and metabolism
JF - Journal of clinical endocrinology and metabolism
IS - 10
ER -